Association of Progranulin Gene Expression from Dyspeptic Patients with Virulent Strains; In Vivo Model

Overview

Journal Microorganisms

Specialty Microbiology

Date 2022 May 28

PMID 35630441

Authors

Claudia Troncoso

Monica Pavez

Alvaro Cerda

Victor Manriquez

Aurora Prado

Edmundo Hofmann

Eddy Rios

Armando Sierralta

Luis Copelli

Leticia Barrientos

Affiliations

Soon will be listed here.

Abstract

(1) Background: Gastric cancer, the fourth most common cause of death from tumors in the world, is closely associated with . Timely diagnosis, therefore, is essential to achieve a higher survival rate. In Chile, deaths from gastric cancer are high, mainly due to late diagnosis. Progranulin has reflected the evolution of some cancers, but has been poorly studied in gastric lesions. Aiming to understand the role of progranulin in infection and its evolution in development of gastric lesions, we evaluated the genic expression of progranulin in gastric tissue from infected and non-infected patients, comparing it according to the epithelial status and virulence of strains. (2) Methods: The genic expression of progranulin by q-PCR was quantified in gastric biopsies from Chilean dyspeptic patients ( = 75) and individuals who were uninfected ( = 75) by , after receiving prior informed consent. Bacteria were grown on a medium Columbia agar with equine-blood 7%, antibiotics (Dent 2%, Oxoid), in a microaerophilic environment, and genetically characterized for the , , , and genes by PCR. The status of the tissue was determined by endoscopic observation. (3) Results: Minor progranulin expression was detected in atrophic tissue, with a sharp drop in the tissue colonized by that carried greater virulence, VacAs1m1CagAIceA1. (4) Conclusions: Progranulin shows a differential behavior according to the lesions and virulence of , affecting the response of progranulin against gastric inflammation.

References

Jian J, Li G, Hettinghouse A, Liu C . Progranulin: A key player in autoimmune diseases. Cytokine. 2016; 101:48-55. PMC: 5303690. DOI: 10.1016/j.cyto.2016.08.007. View

Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfertheiner P . Gastritis: The clinico-pathological spectrum. Dig Liver Dis. 2021; 53(10):1237-1246. DOI: 10.1016/j.dld.2021.03.007. View

Reddy K, Chang J, Shi J, Wu B . Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System. Clin Gastroenterol Hepatol. 2016; 14(10):1420-5. DOI: 10.1016/j.cgh.2016.05.045. View

da Costa D, Dos Santos Pereira E, Rabenhorst S . What exists beyond cagA and vacA? Helicobacter pylori genes in gastric diseases. World J Gastroenterol. 2015; 21(37):10563-72. PMC: 4588078. DOI: 10.3748/wjg.v21.i37.10563. View

Ramirez Ramos A, Sanchez Sanchez R . [Helicobacter pylori 25 years after (1983 -2008): epidemiology, microbiology, pathogenics, diagnostics and treatment]. Rev Gastroenterol Peru. 2009; 29(2):158-70. View

Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M . Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi144-8. DOI: 10.1093/annonc/mdt343. View

Correa P . The biological model of gastric carcinogenesis. IARC Sci Publ. 2004; (157):301-10. View

Palframan S, Kwok T, Gabriel K . Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol. 2012; 2:92. PMC: 3417644. DOI: 10.3389/fcimb.2012.00092. View

Gobert A, Wilson K . Induction and Regulation of the Innate Immune Response in Helicobacter pylori Infection. Cell Mol Gastroenterol Hepatol. 2022; 13(5):1347-1363. PMC: 8933844. DOI: 10.1016/j.jcmgh.2022.01.022. View

10.

Tserentogtokh T, Gantuya B, Subsomwong P, Oyuntsetseg K, Bolor D, Erdene-Ochir Y . Western-Type CagA are the Most Frequent Type in Mongolian Patients. Cancers (Basel). 2019; 11(5). PMC: 6562502. DOI: 10.3390/cancers11050725. View

11.

Zhang L, Liu Y, You P, Feng G . Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up. Scand J Gastroenterol. 2018; 53(7):843-848. DOI: 10.1080/00365521.2018.1477987. View

12.

Kawahara Y, Nakase Y, Isomoto Y, Matsuda N, Amagase K, Kato S . Role of macrophage colony-stimulating factor (M-CSF)-dependent macrophages in gastric ulcer healing in mice. J Physiol Pharmacol. 2011; 62(4):441-8. View

13.

Baroni M, Bucci P, Giani R, Giusti A, Tedeschi F, Salvatierra E . Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Rev Argent Microbiol. 2018; 50(4):359-364. DOI: 10.1016/j.ram.2017.11.005. View

14.

He Z, Ong C, Halper J, Bateman A . Progranulin is a mediator of the wound response. Nat Med. 2003; 9(2):225-9. DOI: 10.1038/nm816. View

15.

Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K . Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun. 2009; 78(1):468-76. PMC: 2798195. DOI: 10.1128/IAI.00903-09. View

16.

Gharibi S, Falsafi T, Alebouyeh M, Farzi N, Vaziri F, Zali M . Relationship between histopathological status of the Helicobacter pylori infected patients and proteases of H. pylori in isolates carrying diverse virulence genotypes. Microb Pathog. 2017; 110:100-106. DOI: 10.1016/j.micpath.2017.06.023. View

17.

Tang C, Hao B, Zhang G, Shi R, Cheng W . Helicobacter pylori tumor necrosis factor-α inducing protein promotes cytokine expression via nuclear factor-κB. World J Gastroenterol. 2013; 19(3):399-403. PMC: 3554826. DOI: 10.3748/wjg.v19.i3.399. View

18.

Atherton J . The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2007; 1:63-96. DOI: 10.1146/annurev.pathol.1.110304.100125. View

19.

Cook K, Letley D, Ingram R, Staples E, Skjoldmose H, Atherton J . CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa. Gut. 2014; 63(10):1550-9. PMC: 4173663. DOI: 10.1136/gutjnl-2013-306253. View

20.

Qian S, Golubnitschaja O, Zhan X . Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019; 10(4):365-381. PMC: 6882964. DOI: 10.1007/s13167-019-00194-x. View